Published in BMC Immunol on April 12, 2010
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Cancer immunology--analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol (2011) 2.90
Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig Dis Sci (2011) 1.77
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer (2014) 1.51
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer (2013) 1.30
Ex-vivo clonally expanded B lymphocytes infiltrating colorectal carcinoma are of mature immunophenotype and produce functional IgG. PLoS One (2012) 1.06
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Front Genet (2013) 0.99
Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One (2011) 0.97
An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. Virchows Arch (2012) 0.96
Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses. Anticancer Res (2014) 0.93
An MSI tumor specific frameshift mutation in a coding microsatellite of MSH3 encodes for HLA-A0201-restricted CD8+ cytotoxic T cell epitopes. PLoS One (2011) 0.93
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. J Immunol Res (2014) 0.92
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma. Int J Biol Sci (2013) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Prognostic biomarkers in colorectal cancer: where do we stand? Virchows Arch (2014) 0.87
The in situ local immune response, tumour senescence and proliferation in colorectal cancer. Br J Cancer (2013) 0.87
A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Prognostic stratification of colorectal cancer patients: current perspectives. Cancer Manag Res (2014) 0.85
Review of histopathological and molecular prognostic features in colorectal cancer. Cancers (Basel) (2011) 0.85
Clinicopathological analysis of colorectal cancer: a comparison between emergency and elective surgical cases. World J Surg Oncol (2013) 0.84
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin Cancer Res (2014) 0.84
Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer. Immunity (2016) 0.83
Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother (2014) 0.82
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One (2012) 0.82
Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration. Oncoimmunology (2013) 0.82
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J Transl Med (2013) 0.81
Sequential metastases of colorectal cancer: Immunophenotypes and spatial distributions of infiltrating immune cells in relation to time and treatments. Oncoimmunology (2012) 0.81
Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest. Biochem Pharmacol (2012) 0.81
Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer (2016) 0.80
T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. Clin Dev Immunol (2011) 0.80
Image analyzer-based assessment of tumor-infiltrating T cell subsets and their prognostic values in colorectal carcinomas. PLoS One (2015) 0.79
Expansion of anti-mesothelin specific CD4+ and CD8+ T cell responses in patients with pancreatic carcinoma. PLoS One (2014) 0.78
The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers. Oncotarget (2015) 0.78
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78
Prognostic value of colorectal cancer biomarkers. Cancers (Basel) (2011) 0.77
Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology (2016) 0.77
Immunological Landscape and Clinical Management of Rectal Cancer. Front Immunol (2016) 0.77
High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer. Int J Clin Exp Pathol (2015) 0.77
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Medulloblastoma-biology and microenvironment: a review. Pediatr Hematol Oncol (2012) 0.76
Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLoS One (2015) 0.75
Cytotoxic T-cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability. J Proteome Res (2015) 0.75
On the prognostic & predictive impact of immune cells system in colorectal cancer. Indian J Med Res (2012) 0.75
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. J Clin Med (2016) 0.75
Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope? World J Gastroenterol (2012) 0.75
FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol Lett (2016) 0.75
High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. Proteomes (2014) 0.75
Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. EJNMMI Res (2015) 0.75
The changes of angiogenesis and immune cell infiltration in the intra- and peri-tumoral melanoma microenvironment. Int J Mol Sci (2015) 0.75
Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy. Int J Colorectal Dis (2015) 0.75
The Clinical Impact of Tumour-infiltrating Lymphocytes in Colorectal Cancer Differs by Anatomical Subsite: A Cohort Study. Int J Cancer (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA (1990) 5.77
Colorectal cancer. Lancet (2005) 4.90
A new prognostic classification of rectal cancer. Lancet (1987) 3.56
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol (1997) 3.09
Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer (2001) 2.82
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol (1999) 2.80
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
Inflammation and prognosis in colorectal cancer. Eur J Cancer (2005) 2.47
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg (2009) 2.22
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol (2001) 2.13
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother (2003) 2.11
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest (2004) 2.05
Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer (2004) 1.98
Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol (2004) 1.89
Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol (1999) 1.86
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer (2004) 1.80
The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer (2005) 1.69
Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol (2003) 1.61
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer (2005) 1.59
Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences. Am J Pathol (1998) 1.55
Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer (2001) 1.53
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer (2006) 1.52
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg (2004) 1.49
Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun (2007) 1.43
Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res (2003) 1.38
Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep (2003) 1.37
Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer (1999) 1.36
Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg (2006) 1.31
Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. Gut (2000) 1.21
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology (2003) 1.16
Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer (2006) 1.16
Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer (2009) 1.15
The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun (2009) 1.14
The immune system and cancer. Cancer Biother Radiopharm (2009) 1.11
Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer (2007) 1.10
Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther (2006) 1.09
Microsatellite instability in sporadic colorectal carcinoma is not an indicator of prognosis. J Pathol (1999) 1.09
Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol Rep (2005) 1.02
The immunogenicity of colorectal cancers with high-degree microsatellite instability. World J Surg Oncol (2005) 1.01
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn (2008) 0.99
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer (2009) 0.98
Tumor-infiltrating T cells--friend or foe of neoplastic cells? N Engl J Med (2005) 0.98
The correlation of microsatellite instability and tumor-infiltrating lymphocytes in hereditary non-polyposis colorectal cancer (HNPCC) and sporadic colorectal cancers: the significance of different types of lymphocyte infiltration. Jpn J Clin Oncol (2004) 0.95
Prognostic significance of microsatellite instability in sporadic mucinous colorectal cancers. Hum Pathol (1999) 0.95
Molecular prognostic markers in locally advanced colon cancer. Clin Colorectal Cancer (2007) 0.94
The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol Immunother (2002) 0.94
Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother (2007) 0.92
Mechanisms of lysis by cytotoxic T cells. Crit Rev Immunol (1995) 0.89
Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Ann Oncol (2004) 0.88
Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer. J Clin Lab Anal (2006) 0.85
Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer (2008) 0.84
Active specific immunotherapy in colon cancer. Recent Results Cancer Res (2005) 0.80
Adjuvant therapy of colon cancer. Semin Oncol (1995) 0.77
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature (2008) 5.05
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol (2013) 3.36
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLoS One (2007) 3.27
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol (2009) 3.19
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer (2003) 2.36
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12
Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev (2010) 2.09
Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw. Clin Nucl Med (2011) 2.04
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Investigations on the biology, epidemiology, pathology and control of Tunga penetrans in Brazil: I. Natural history of tungiasis in man. Parasitol Res (2003) 1.94
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
Body mass index trajectory classes and incident asthma in childhood: results from 8 European Birth Cohorts--a Global Allergy and Asthma European Network initiative. J Allergy Clin Immunol (2013) 1.71
Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One (2012) 1.70
Distribution of human papillomavirus in a family planning population in nairobi, kenya. Sex Transm Dis (2003) 1.60
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res (2006) 1.58
Investigations on the biology, epidemiology, pathology and control of Tunga penetrans in Brazil: IV. Clinical and histopathology. Parasitol Res (2004) 1.58
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol (2003) 1.57
Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes. Cancer Biol Ther (2009) 1.55
Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.53
Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril (2007) 1.48
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J (2009) 1.47
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol (2004) 1.42
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41
Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies. J Clin Microbiol (2010) 1.40
Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial. J Surg Oncol (2007) 1.40
The prospect of biologic staging of non-small-cell lung cancer. Clin Lung Cancer (2005) 1.39
Prognostic value of smoking status in operated non-small cell lung cancer. Lung Cancer (2005) 1.33
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res (2013) 1.30
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer (2012) 1.27
Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol (2004) 1.26
Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int J Parasitol (2003) 1.26
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist (2010) 1.26
Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist (2007) 1.24
Molecular therapy in head and neck oncology. Nat Rev Clin Oncol (2009) 1.24
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol (2004) 1.22
An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One (2012) 1.17
Combined modality therapy of gemcitabine and radiation. Oncologist (2005) 1.17
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. Trop Med Int Health (2004) 1.16
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin. Hum Pathol (2005) 1.15
Herpes simplex virus in the respiratory tract of critical care patients: a prospective study. Lancet (2003) 1.15
Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J Antimicrob Chemother (2005) 1.12
Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol (2002) 1.11
RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiat Oncol (2013) 1.08
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs (2007) 1.08
In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg (2005) 1.08
Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis (2003) 1.08
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol (2005) 1.08
Mycobacterium ulcerans disease, Peru. Emerg Infect Dis (2008) 1.07
Expression and nuclear location of the transcriptional repressor Kaiso is regulated by the tumor microenvironment. Cancer Res (2005) 1.06
Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infect Genet Evol (2003) 1.05
Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck (2014) 1.02
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol Oncol (2012) 1.02
RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer (2011) 1.02
Multiplex PCR with minisequencing as an effective high-throughput SNP typing method for formalin-fixed tissue. Electrophoresis (2007) 1.02
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Taxanes in the treatment of head and neck cancer. Curr Opin Oncol (2005) 0.99
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn (2008) 0.99
Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol (2008) 0.99
Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI. Cancer Microenviron (2011) 0.99
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res (2014) 0.99
Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. BMC Biotechnol (2009) 0.98
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol (2008) 0.98
Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther (2011) 0.98
Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer. Clin Cancer Res (2008) 0.98
Clinical potential of intravenous neural stem cell delivery for treatment of neuroinflammatory disease in mice? Cell Transplant (2010) 0.98
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Breast Cancer Res (2014) 0.97
Pervasive developmental disorders in Prader-Willi syndrome: the Leuven experience in 59 subjects and controls. Am J Med Genet A (2006) 0.96
Investigations on the biology, epidemiology, pathology and control of Tunga penetrans in Brazil. VI. Natural history of the infestation in laboratory-raised Wistar rats. Parasitol Res (2007) 0.95
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer (2012) 0.95
Atypical presentation of an atypical carcinoid. Ann Thorac Surg (2009) 0.95
Modeling and characterization of inflammatory breast cancer emboli grown in vitro. Int J Cancer (2012) 0.95
Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol (2012) 0.94
Needle autopsy to establish the cause of death in HIV-infected hospitalized adults in Uganda: a comparison to complete autopsy. J Acquir Immune Defic Syndr (2014) 0.94
Endobronchial lipomas: rare benign lung tumors, two case reports. J Thorac Oncol (2009) 0.94
In vivo antioxidative activity of a quantified Pueraria lobata root extract. J Ethnopharmacol (2009) 0.94
Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol (2002) 0.93